BioNet News 03 Jan 2025 BioNet’s Support for Local Communities BioNet recently teamed up with the Social Development and Human Security Office of Ayutthaya, and local volunteers to visit vulnerable… Supachai
BioNet News 31 Dec 2024 A reduced-dose recombinant pertussis vaccine booster in Thai adolescents: a phase 2/3, observer-blinded, randomised controlled, non-inferiority trial Pertussis, also known as whooping cough, is an acute respiratory disease caused by Bordetella pertussis, a bacterium that is transmitted between… Pantitra
BioNet News 30 Dec 2024 Pertussis Immunity 5 Years After Booster Vaccination With Recombinant Pertussis Vaccines Pertussis remains one of the least controlled vaccine-preventable diseases. Pertussis booster vaccines are associated with fast-waning immunity and offer only… Pantitra
BioNet News 31 Jul 2024 BioNet Recombinant Pertussis Vaccine Submitted to EMA BioNet’s Recombinant Pertussis Vaccine Submitted to European Medicines Agency (EMA) "Monovalent recombinant acellular pertussis vaccine proven to significantly boost immunity… Supachai
BioNet News 30 Jul 2024 Transplacental transfer of maternal antibodies following immunization with recombinant pertussis vaccines during pregnancy: Real-world evidence Pertussis, caused by Bordetella pertussis, is a highly contagious respiratory disease that poses a significant risk to young infants, resulting in both severe morbidity… Pantitra
BioNet News 17 May 2024 First study to assess placental transfer of maternal antibodies after immunization with recombinant pertussis vaccines during pregnancy Pertussis (whooping cough), caused by Bordetella pertussis, is a highly contagious respiratory disease responsible for severe morbidity and about 4%… Supachai
BioNet News 05 Apr 2024 BioNet aP on its way to support Thailand’s Universal Coverage Scheme, managed by NHSO The shipment is underway. Our acellular pertussis vaccines (aP) are officially on the move, heading to support the Universal Coverage… Pantitra
BioNet News 12 Jan 2024 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Recombinant acellular pertussis (ap) vaccines containing genetically inactivated pertussis toxin (PTgen) and filamentous hemagglutinin (FHA) with or without tetanus (TT)… Pantitra
BioNet News 12 Dec 2023 Effective and safe transfer of maternal antibodies persisting two months postpartum following maternal immunization with different doses of recombinant pertussis-containing vaccines Highlights • Recombinant pertussis vaccine is safe for both mother and newborn. • There is effective transplacental antibody transfer to… Supachai
BioNet News 22 Jun 2023 A phase 2 randomized controlled dose-ranging trial of recombinant pertussis booster vaccines containing genetically inactivated pertussis toxin in pregnant women Highlights • Recombinant acellular pertussis vaccine is safe and immunogenic in pregnant women. • Vaccine formulations containing PTgen were non-inferior… Supachai
